The Evolutionary Landscape of Treatment for <i>BRAF<sup>V600E</sup></i> Mutant Metastatic Colorectal Cancer

The Evolutionary Landscape of Treatment for <i>BRAF<sup>V600E</sup></i> Mutant Metastatic Colorectal Cancer

The <i>BRAF<sup>V600E</sup></i> mutation is found in 8–10% of metastatic colorectal cancer (mCRC) patients and it is recognized as a poor prognostic factor with a median overall survival inferior to 20 months. At present, besides immune checkpoint inhibitors (CPIs) for those...

Full description

Bibliographic Details
Main Authors: Gianluca Mauri, Erica Bonazzina, Alessio Amatu, Federica Tosi, Katia Bencardino, Viviana Gori, Daniela Massihnia, Tiziana Cipani, Francesco Spina, Silvia Ghezzi, Salvatore Siena, Andrea Sartore-Bianchi
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
<i>BRAF</i>
colon cancer
immune checkpoint inhibitors
targeted agents
FOLFOXIRI
Online Access:https://www.mdpi.com/2072-6694/13/1/137

Internet

https://www.mdpi.com/2072-6694/13/1/137

Similar Items